SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

July 31, 2015 13:00 ET

Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results

Corporate Update Call at 10:00 am ET August 12, 2015

BUFFALO, NY--(Marketwired - Jul 31, 2015) -  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on August 12, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015, and will host a conference call at 10:00 a.m. ET. 

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com

A replay of the call will be available starting on August 12, 2015, at 1:00 p.m. ET through August 26, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13613931. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

Contact Information

  • Contact:
    Rachel Levine
    Vice President Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935
    Email: rlevine@cbiolabs.com